journal
https://read.qxmd.com/read/37751397/assessment-of-treatment-response-on-facial-vitiligo-a-step-forward-but-what-about-the-neck
#1
EDITORIAL
Viktoria Eleftheriadou, Julien Seneschal
No abstract text is available yet for this article.
September 26, 2023: British Journal of Dermatology
https://read.qxmd.com/read/37751385/drug-survival-of-metformin-in-patients-with-hidradenitis-suppurativa
#2
JOURNAL ARTICLE
Marina Senent-Valero, Alicia Matijasevich, Noelia Jara-Rico, Francisca Sivera, José C Pascual
No abstract text is available yet for this article.
September 26, 2023: British Journal of Dermatology
https://read.qxmd.com/read/37742065/correction-to-tmem232-promotes-the-inflammatory-response-in-atopic-dermatitis-via-the-nuclear-factor-%C3%AE%C2%BAb-and-signal-transducer-and-activator-of-transcription-3-signalling-pathways
#3
(no author information available yet)
No abstract text is available yet for this article.
September 23, 2023: British Journal of Dermatology
https://read.qxmd.com/read/37742060/when-science-and-evidence-is-not-enough-challenging-the-recommendations-from-the-commission-on-human-medicines-isotretinoin-expert-working-group
#4
JOURNAL ARTICLE
Eugene Tan, Harriet Kennedy, Marius Rademaker
No abstract text is available yet for this article.
September 23, 2023: British Journal of Dermatology
https://read.qxmd.com/read/37740985/correction-to-the-aggressive-behaviour-of-squamous-cell%C3%A2-carcinoma-in-epidermolysis-bullosa-analysis-of-clinical%C3%A2-outcomes-and-tumour-characteristics-in-the-dutch%C3%A2-eb-registry
#5
JOURNAL ARTICLE
(no author information available yet)
No abstract text is available yet for this article.
September 23, 2023: British Journal of Dermatology
https://read.qxmd.com/read/37740959/correction-to-efficacy-and-safety-of-topical-brepocitinib-cream-for-mild-to-moderate-chronic-plaque-psoriasis-a%C3%A2-phase-iib-randomized-double-blind-vehicle-controlled-parallel-group-study
#6
(no author information available yet)
No abstract text is available yet for this article.
September 23, 2023: British Journal of Dermatology
https://read.qxmd.com/read/37740557/british-association-of-dermatologists-guidelines-for-biologic-therapy-for-psoriasis-2023-a-pragmatic-update
#7
JOURNAL ARTICLE
Catherine H Smith, Zenas Z N Yiu, Tracy Bale, A David Burden, Laura C Coates, Elizabeth Eckert, Nicky Longley, Satveer K Mahil, Arlene McGuire, Ruth Murphy, Catherine Nelson-Piercy, Caroline M Owen, Richard Parslew, Richard T Woolf, Zahra Mansour Kiaee, Alina M Constantin, Martinsixtus C Ezejimofor, Lesley S Exton, M Firouz Mohd Mustapa
No abstract text is available yet for this article.
September 22, 2023: British Journal of Dermatology
https://read.qxmd.com/read/37739394/expanding-the-feasibility-of-large-genomics-skin-studies-using-epidermal-dna-collected-via-tape-stripping
#8
JOURNAL ARTICLE
Amanda E Toland
No abstract text is available yet for this article.
September 22, 2023: British Journal of Dermatology
https://read.qxmd.com/read/37722926/efficacy-and-safety-of-ciclosporin-versus-methotrexate-in-the-treatment-of-severe-atopic-dermatitis-in-children-and-young-people-treat-a-multicentre-parallel-group-assessor-blinded-clinical-trial
#9
JOURNAL ARTICLE
Carsten Flohr, Anna Rosala-Hallas, Ashley P Jones, Paula Beattie, Susannah Baron, Fiona Browne, Sara J Brown, Joanna E Gach, Danielle Greenblatt, Ross Hearn, Eva Hilger, Ben Esdaile, Michael J Cork, Emma Howard, Marie-Louise Lovgren, Suzannah August, Farhiya Ashoor, Paula R Williamson, Tess McPherson, Donal O'Kane, Jane Ravenscroft, Lindsay Shaw, Manish D Sinha, Catherine Spowart, Leonie S Taams, Bjorn R Thomas, Mandy Wan, Tracey H Sach, Alan D Irvine
BACKGROUND: Conventional systemic drugs are used to treat children and young people (CYP) with severe atopic dermatitis (AD) worldwide, but no robust RCT evidence exists regarding their efficacy and safety in this population. While novel therapies have expanded therapeutic options, their high cost means traditional agents remain important, especially in lower resource settings. OBJECTIVES: The TREAT trial compared the safety and efficacy of ciclosporin (CyA) versus methotrexate (MTX) in CYP with severe AD...
September 19, 2023: British Journal of Dermatology
https://read.qxmd.com/read/37715694/hidradenitis-suppurativa-new-insights-into-disease-mechanisms-and-an-evolving-treatment-landscape
#10
JOURNAL ARTICLE
James G Krueger, John Frew, Gregor B E Jemec, Alexa B Kimball, Brian Kirby, Falk G Bechara, Kristina Navrazhina, Errol Prens, Kristian Reich, Eva Cullen, Kerstin Wolk
Hidradenitis suppurativa (HS), also known as acne inversa, is a chronic disabling and debilitating inflammatory disease with high unmet medical need. The prevalence of HS is 1-2% in most studies, although it is likely underreported and estimates vary globally due to variance in data collection methods, ethnicity, geographical location, and underdiagnosis. HS is characterized by persistent, painful cutaneous nodules, abscesses, and draining tunnels commonly affecting the axillary, anogenital, inguinal, and perianal/gluteal areas...
September 16, 2023: British Journal of Dermatology
https://read.qxmd.com/read/37713632/multiple-primary-melanoma-risk-factors-reviewed
#11
EDITORIAL
Remco van Doorn
No abstract text is available yet for this article.
September 15, 2023: British Journal of Dermatology
https://read.qxmd.com/read/37713611/evaluating-the-usefulness-of-the-atopic-dermatitis-control-tool-for-assessing-disease-control-among-individuals-with-atopic-dermatitis-in-japan
#12
JOURNAL ARTICLE
Takeshi Nakahara, Hiroyuki Fujita, Yuki Tajima, Kazuhiko Arima
No abstract text is available yet for this article.
September 15, 2023: British Journal of Dermatology
https://read.qxmd.com/read/37708291/correction-to-partner-bereavement-and-risk-of-psoriasis-and-atopic-eczema-cohort-studies-in-the-u-k-and-denmark-and-to-partner-bereavement-and-risk-of-chronic-urticaria-alopecia-areata-and-vitiligo-cohort-studies-in-the-uk-and-denmark
#13
https://read.qxmd.com/read/37708254/when-to-expect-scalp-hair-regrowth-during-treatment-of-severe-alopecia-areata-with-baricitinib-insights-from-trajectories-analyses-of-patients-enrolled-in-two-phase-iii-trials
#14
JOURNAL ARTICLE
Brett King, Jerry Shapiro, Manabu Ohyama, Alexander Egeberg, Bianca Maria Piraccini, Brittany Craiglow, Rodney Sinclair, Yun-Fei Chen, Wen-Shuo Wu, Yuxin Ding, Najwa Somani, Yves Dutronc
BACKGROUND: Baricitinib is approved for the treatment of adults with severe alopecia areata (AA). In the absence of robust data on the patterns of regrowth during treatment of severe AA, there is a gap in the knowledge regarding treatment expectations. OBJECTIVES: To examine whether different clinical response subgroups could be identified in baricitinib-treated patients with severe AA and factors that contribute to these subgroups. METHODS: The BRAVE-AA1 and BRAVE-AA2 phase III trials enrolled patients with severe AA [Severity of Alopecia Tool (SALT) score ≥ 50 (≥ 50% scalp hair loss)]...
September 14, 2023: British Journal of Dermatology
https://read.qxmd.com/read/37705227/the-global-epidemiology-of-atopic-dermatitis-a-comprehensive-systematic-analysis-and-modelling-study
#15
JOURNAL ARTICLE
Jingru Tian, Dingyao Zhang, Yi Yang, Yaqing Huang, Lu Wang, Xu Yao, Qianjin Lu
BACKGROUND: Atopic dermatitis (AD) is the leading cause of the global burden from skin disease, while none of the study provides the global and country-specific AD epidemiological estimates. OBJECTIVE: To quantify global, regional, and country-specific estimates of epidemiology of AD. METHODS: A comprehensive search for AD epidemiological studies was conducted across four electronic databases-PubMed, EMBASE, Web of Science, and China National Knowledge Infrastructure...
September 14, 2023: British Journal of Dermatology
https://read.qxmd.com/read/37705206/global-valiant-study-lifting-the-lid-on-disappointment-and-frustration-with-lack-of-effective-treatment-for-vitiligo
#16
EDITORIAL
Alia Ahmed, Viktoria Eleftheriadou
No abstract text is available yet for this article.
September 14, 2023: British Journal of Dermatology
https://read.qxmd.com/read/37703325/targeting-il-4-il-13-in-immune-checkpoint-inhibitor-induced-bullous-pemphigoid-a-cautionary-note-on-the-beneficial-effect-of-th2-in-melanoma-and-immunotherapy
#17
JOURNAL ARTICLE
Christian F Guerrero-Juarez, Parul K Goyal, Kyle T Amber
No abstract text is available yet for this article.
September 13, 2023: British Journal of Dermatology
https://read.qxmd.com/read/37697683/izokibep-for-the-treatment-of-moderate-to-severe-plaque-psoriasis-a-phase-ii-randomized-placebo-controlled-double-blind-dose-finding-multicentre-study-including-long-term-treatment
#18
JOURNAL ARTICLE
Sascha Gerdes, Petra Staubach, Thomas Dirschka, Dieter Wetzel, Oliver Weirich, Johannes Niesmann, Rodrigo da Mota, Alex Rothhaar, Michael Ardabili, Gerda Vlasitz, Joachim Feldwisch, Lisa Osterling Koskinen, Sven Ohlman, Paul M Peloso, Nikolai C Brun, Fredrik Y Frejd
BACKGROUND: Monoclonal antibodies to interleukin (IL)-17 have shown strong efficacy in patients with psoriasis. Izokibep is a unique IL-17A inhibitor with a small molecular size and favourable distribution to sites of inflammation. OBJECTIVES: To evaluate the dose response, efficacy and safety of izokibep in patients with plaque psoriasis. METHODS: In this double-blind, randomized, phase II dose-finding study (AFFIRM-35) in adults with moderate-to-severe plaque psoriasis and inadequate response to two or more standard therapies, patients were randomized (1:1:1:1:1) to placebo or izokibep 2, 20, 80 or 160 mg every 2 weeks for 12 weeks...
September 12, 2023: British Journal of Dermatology
https://read.qxmd.com/read/37681515/a-superb-way-to-split-hairs
#19
JOURNAL ARTICLE
Jane Li, Jack Green
No abstract text is available yet for this article.
September 8, 2023: British Journal of Dermatology
https://read.qxmd.com/read/37681509/mir-200b-mediated-reversion-of-a-spectrum-of-epithelial-to-mesenchymal-transition-states-in-recessive-dystrophic-epidermolysis-bullosa-squamous-cell-carcinomas
#20
JOURNAL ARTICLE
Julia Illmer, Roland Zauner, Josefina Piñón Hofbauer, Monika Wimmer, Stefanie Gruner, Michael Ablinger, Johannes Bischof, Sonja Dorfer, Stefan Hainzl, Vanessa Tober, Shir Bergson, Ofer Sarig, Liat Samuelov, Christina Guttmann-Gruber, Ruby Shalom-Feuerstein, Eli Sprecher, Ulrich Koller, Martin Laimer, Johann W Bauer, Verena Wally
BACKGROUND: Cutaneous squamous cell carcinomas (SCC) are the leading cause of death in patients suffering from recessive dystrophic epidermolysis bullosa (RDEB). However, the survival time from first diagnosis differs among patients, and some tumours spread particularly fast, while others may remain localised over years. As treatment options are limited, there is an urgent need to provide further insights into the pathomechanisms elucidating the clinical heterogeneity of RDEB tumours to foster therapy development and support clinical decision-making...
September 8, 2023: British Journal of Dermatology
journal
journal
20056
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.